Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity
Sign Up to like & getrecommendations! Published in 2018 at "European Journal of Nuclear Medicine and Molecular Imaging"
DOI: 10.1007/s00259-018-3945-z
Abstract: PurposePeptide receptor radionuclide therapy in patients with neuroendocrine tumours has yielded promising results. This prospective study investigated the feasibility of dosimetry of the kidneys and bone marrow during therapy and its impact on efficacy and… read more here.
Keywords: study; toxicity; dota octreotate; 177lu dota ... See more keywords
Safety and dosimetry of [177Lu]Lu-DOTA-TATE in adolescent patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours, or pheochromocytomas and paragangliomas: Primary analysis of the Phase II NETTER-P study
Sign Up to like & getrecommendations! Published in 2025 at "European Journal of Nuclear Medicine and Molecular Imaging"
DOI: 10.1007/s00259-025-07246-7
Abstract: NETTER-P, an open-label Phase II study, evaluated the safety and dosimetry of [177Lu]Lu-DOTA-TATE (hereafter 177Lu-DOTATATE) in adolescents with advanced, somatostatin receptor-positive, well-differentiated, Grade 1/2 gastroenteropancreatic neuroendocrine tumours (GEP-NET) or pheochromocytoma and paragangliomas (PPGL). Patients (12–17… read more here.
Keywords: dota tate; safety dosimetry; dosimetry; safety ... See more keywords
Novel Radiolabeled TMTP1 for Long-Acting Hepatocellular Carcinoma Therapeutics.
Sign Up to like & getrecommendations! Published in 2022 at "Molecular pharmaceutics"
DOI: 10.1021/acs.molpharmaceut.2c00270
Abstract: Currently, the 5-year survival rate for patients with advanced hepatocellular carcinoma (HCC) is very low. Therefore, there is an urgent need to find new strategies for the treatment of HCC. TMTP1 (NVVRQ) is a tumor-homing… read more here.
Keywords: hepatocellular carcinoma; 177lu dota; tmtp1; dota tmtp1 ... See more keywords
Development of Fibroblast Activation Protein Inhibitor-Based Dimeric Radiotracers with Improved Tumor Retention and Antitumor Efficacy.
Sign Up to like & getrecommendations! Published in 2022 at "Molecular pharmaceutics"
DOI: 10.1021/acs.molpharmaceut.2c00424
Abstract: Fibroblast activation protein (FAP), a fundamental component of the tumor stroma, is overexpressed in cancer-associated fibroblasts (CAFs). As a promising theranostic probe, we evaluated whether the FAP inhibitor (FAPI) dimer (DOTA-2P[FAPI]2) is more effective than… read more here.
Keywords: fapi; dota fapi; retention; 177lu dota ... See more keywords
New Radiolabeled Exendin Analogues Show Reduced Renal Retention.
Sign Up to like & getrecommendations! Published in 2023 at "Molecular pharmaceutics"
DOI: 10.1021/acs.molpharmaceut.3c00117
Abstract: PET imaging of the glucagon-like peptide-1 receptor (GLP-1R) using radiolabeled exendin is a promising imaging method to detect insulinomas. However, high renal accumulation of radiolabeled exendin could hamper the detection of small insulinomas in proximity… read more here.
Keywords: renal retention; 177lu dota; nota exendin; 68ga nota ... See more keywords
Real-world comparison of healthcare resource utilization and costs of [177Lu]Lu-DOTA-TATE in patients with progressive neuroendocrine tumors in England: a matched cohort analysis using data from the hospital episode statistics dataset
Sign Up to like & getrecommendations! Published in 2022 at "Current Medical Research and Opinion"
DOI: 10.1080/03007995.2022.2065146
Abstract: Abstract Objective To explore the healthcare resource utilization (HCRU) and costs for patients with progressive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) treated with [177Lu]Lu-DOTA-TATE and matched patients treated with somatostatin analogs (SSAs), chemotherapy, or targeted therapies. Methods… read more here.
Keywords: 177lu dota; utilization; group; dota tate ... See more keywords
Development and Application of Radioactive Ligands Targeting Fibroblasts with Albumin-Binding Sites
Sign Up to like & getrecommendations! Published in 2025 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.mct-24-1108
Abstract: Abstract Fibroblast activation protein (FAP) is overexpressed on cancer-associated fibroblasts, making it an important target for cancer diagnosis and treatment, but limited tumor retention hinders late-stage diagnosis and radionuclide therapy. In this study, three albumin-bound… read more here.
Keywords: tumor; 177lu dota; 68ga 177lu; dota alb ... See more keywords
Targeted beta therapy of prostate cancer with 177Lu-labelled Miltuximab® antibody against glypican-1 (GPC-1)
Sign Up to like & getrecommendations! Published in 2020 at "EJNMMI Research"
DOI: 10.1186/s13550-020-00637-x
Abstract: Chimeric antibody Miltuximab®, a human IgG1 engineered from the parent antibody MIL-38, is in clinical development for solid tumour therapy. Miltuximab® targets glypican-1 (GPC-1), a cell surface protein involved in tumour growth, which is overexpressed… read more here.
Keywords: dota miltuximab; antibody; miltuximab; 177lu dota ... See more keywords
Blood-based transcriptomic biomarkers for response to [177Lu]Lu-DOTA-TATE therapy in neuroendocrine tumors
Sign Up to like & getrecommendations! Published in 2025 at "EJNMMI Research"
DOI: 10.1186/s13550-025-01284-w
Abstract: [177Lu]Lu-DOTA-TATE is an effective treatment for metastatic neuroendocrine tumors (NETs) expressing somatostatin receptors. While the tumor uptake [177Lu]Lu-DOTA-TATE of has shown potential as a predictive biomarker, patient response to the treatment varies significantly. In this… read more here.
Keywords: dota tate; treatment; tate therapy; response ... See more keywords
Prediction of [177Lu]Lu-DOTA-TATE therapy response using the absorbed dose estimated from [177Lu]Lu-DOTA-TATE SPECT/CT in patients with metastatic neuroendocrine tumour
Sign Up to like & getrecommendations! Published in 2024 at "EJNMMI Physics"
DOI: 10.1186/s40658-024-00620-8
Abstract: Peptide receptor radionuclide therapy (PRRT) with [177Lu]Lu-DOTA-TATE has shown efficacy in patients with metastatic neuroendocrine tumours (NETs). Personalised dosimetry is crucial to optimise treatment outcomes and minimise adverse events. In this study, we investigated the… read more here.
Keywords: dota tate; analysis; 177lu dota; lesion ... See more keywords
177Lu-DOTA-TLX591 safety, biodistribution and dosimetry study (ProstACT-SELECT).
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2022.40.16_suppl.tps5109
Abstract: TPS5109 Background: The cell surface glycoprotein prostate-specific membrane antigen (PSMA) has proven to be an ideal therapeutic target in prostate cancer (PC) as it is highly expressed by malignant prostate cells.1,2 177Lu-DOTA-HuJ591-CHO (TLX591) is a… read more here.
Keywords: biodistribution dosimetry; tlx591; safety; 177lu dota ... See more keywords